Improving TRAIL-induced apoptosis in cancers by interfering with histone modifications  

作　　者：Bao-Jie Zhang Deng Chen Frank J.Dekker Wim J.Quax 

机构地区：[1]University of Groningen,Department of Chemical and Pharmaceutical Biology,Groningen Research Institute of Pharmacy,University of Groningen,Groningen 9713 AV,The Netherlands

出　　处：《Cancer Drug Resistance》2020年第4期791-803,共13页癌症耐药（英文）

基　　金：This research was partly funded by The Dutch Technology Foundation(STW)(No.11056);European Fund for Regional Development(KOP/EFRO)(No.068 and No.073).

摘　　要：Epigenetic regulation refers to alterations to the chromatin template that collectively establish differential patterns of gene transcription.Post-translational modifications of the histones play a key role in epigenetic regulation of gene transcription.In this review,we provide an overview of recent studies on the role of histone modifications in carcinogenesis.Since tumour-selective ligands such as tumor necrosis factor-related apoptosis-inducing ligand(TRAIL)are well-considered as promising anti-tumour therapies,we summarise strategies for improving TRAIL sensitivity by inhibiting aberrant histone modifications in cancers.In this perspective we also discuss new epigenetic drug targets for enhancing TRAIL-mediated apoptosis.

关 键 词：EPIGENETICS histone modification tumor necrosis factor-related apoptosis-inducing ligand selective epigenetic inhibitors APOPTOSIS 

分 类 号：R73[医药卫生—肿瘤]